Macro and Strategy - June financial data shows a significant rebound in credit, with new social financing reaching 4.20 trillion yuan, exceeding expectations of 3.71 trillion yuan, and new RMB loans at 2.24 trillion yuan, surpassing the forecast of 1.84 trillion yuan [8][9][10] - The M2 money supply grew by 8.3% year-on-year, indicating a recovery in domestic economic momentum as private sector balance sheet expansion improves [8][9] - The "seesaw effect" between government financing and corporate loans has weakened, suggesting a shift in credit dynamics as local governments approach their annual debt targets [9][10] Retail Industry - The jewelry market is projected to grow steadily, with the market size reaching 728 billion yuan in 2024, reflecting a compound annual growth rate of 3.6% since 2019 [11][12] - The top five companies in the jewelry sector hold a market share of 41.4%, indicating increasing industry concentration as consumer preferences shift towards quality and design [11][12] - The retail sector is benefiting from the recent Amazon Prime Day, which generated an estimated $24.1 billion in sales, a 30% increase year-on-year, highlighting the growth potential in cross-border e-commerce [13][14] Food and Beverage Industry - The food and beverage sector saw a 0.92% increase, underperforming the Shanghai Composite Index by 0.17 percentage points [14] - The liquor market is stabilizing, with major brands focusing on brand positioning and market health, while the overall demand remains under pressure [15][16] - Recommendations include leading brands like Kweichow Moutai and Wuliangye, which have shown resilience and potential for recovery [15][16] Construction and Building Materials - The construction materials sector is expected to improve due to a shift towards healthy competition and urban renewal initiatives, with a focus on technological innovation [17][18] - Cement prices have stabilized, with a slight decrease of 0.4% week-on-week, while demand remains steady despite seasonal fluctuations [17][18] - Recommendations include companies like Three Trees and China National Building Material, which are well-positioned to benefit from domestic demand [18] Computer Industry - The AI ASIC market is rapidly expanding, with a projected market size growth from $14.8 billion in 2024 to $83.8 billion by 2030, reflecting a compound annual growth rate of 33.5% [19][20] - The price advantage of AI ASIC chips over GPUs is significant, with average prices of $5,236 compared to $8,001 for GPUs, making them more attractive for specific applications [19][20] - Companies like Google and Amazon are accelerating their development of ASIC chips, indicating strong future demand in this sector [21] Home Appliances - The home appliance sector is experiencing stable growth in domestic sales, driven by government subsidies, while exports face challenges due to high bases and tariff impacts [22][23] - White goods are seeing a slight increase in domestic sales, with air conditioning units showing a 9.5% growth in domestic shipments [22][23] - Recommendations include leading brands such as Midea and Gree, which are expected to maintain strong performance [22][23] Pharmaceutical Industry - Merck's acquisition of Verona for $10 billion aims to enhance its portfolio with a new COPD treatment, indicating strong growth potential in respiratory therapies [27][28] - WuXi AppTec is projected to achieve a 102% increase in net profit for the first half of 2025, reflecting robust operational performance [29] - The pharmaceutical sector is showing resilience, with a focus on innovative treatments and strategic acquisitions [27][28] Coal Industry - The coal market is expected to stabilize as domestic production increases and imports decrease, with a projected production of 4.85 billion tons in 2025, a 2% increase year-on-year [31][32] - Demand for coal is anticipated to improve in the second half of the year, particularly for non-electric uses such as chemical production [33] - Recommendations include leading coal companies like China Shenhua and China Coal Energy, which are well-positioned to benefit from market dynamics [34] Electronics Industry - The electronics sector is experiencing positive momentum, with a 0.93% increase in stock performance, driven by strong demand in the optical and semiconductor segments [34] - The industry is expected to see significant catalysts in the coming months, particularly in the context of AI and cloud computing advancements [34] - Companies involved in ASIC development are likely to benefit from the ongoing trends in computing and data processing [34]

金融界7月15日消息，A股三大指数收盘涨跌不一，中证等权重90指数 (等权90，000971)上涨0.75%，报 2723.35点，成交额1949.29亿元。 数据统计显示，中证等权重90指数近一个月上涨5.35%，近三个月上涨7.11%，年至今上涨0.98%。 据了解，中证等权重90指数由上证50指数样本和按照上证50指数选样方法在深圳市场中选出的40只上市 公司证券等权重加权组成，综合反映沪深市场规模大、流动性好的90家上市公司证券的整体表现。该指 数以2003年12月31日为基日，以1000.0点为基点。 从中证等权重90指数持仓的市场板块来看，上海证券交易所占比54.47%、深圳证券交易所占比 45.53%。 从中证等权重90指数持仓样本的行业来看，信息技术占比20.84%、工业占比17.63%、金融占比 17.19%、通信服务占比11.14%、可选消费占比8.49%、主要消费占比6.30%、原材料占比5.62%、医药卫 生占比4.42%、能源占比4.17%、公用事业占比2.12%、房地产占比2.09%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) ...

FF305 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | | | | 於下列日期開始時的結存(註1) | 2025年7月14日 | | 2,485,141,055 | | 0 | | 2,485,141,055 | | 1). 其他 (請註明) | | | | % | | | | | 參見B部 | | | | | | | | | 變動日期 | 2025年7月15日 | | | | | | ...

Core Viewpoint - WuXi AppTec Co., Ltd. (药明康德) expects a significant increase in its 2025 half-year performance, with projected revenue of 20.64% growth year-on-year, driven by its integrated CRDMO business model and operational efficiency improvements [1][3]. Group 1: Financial Performance - The company anticipates a revenue of approximately 20.799 billion yuan for the first half of 2025, reflecting a year-on-year increase of about 20.64% [1]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be around 5.582 billion yuan, representing a year-on-year growth of approximately 26.47% [3]. - The impact of non-recurring gains primarily stems from the sale of part of its holdings in WuXiXDC Cayman Inc., with expected gains of about 3.210 billion yuan [3]. Group 2: Market Sentiment and Industry Outlook - Investors are optimistic about the CXO sector, with comments indicating a potential recovery in the innovative drug market [4]. - Analysts from Dongwu Securities highlighted the significant performance turnaround in the sector, noting that companies like WuXi AppTec and others are showing improved growth [4]. - Citigroup's report emphasizes a strong resurgence in interest in the healthcare sector, particularly in innovative drugs, suggesting that the CXO sector will attract more attention due to improved fundamentals and attractive valuations [5].

Group 1 - The core point of the news is that WuXi AppTec's subsidiary, Tianjin WuXi AppTec New Drug Development Co., Ltd., was listed in the administrative penalty announcement but was not penalized for failing to implement emergency response regulations regarding emergency materials and equipment [1][3] - The Tianjin Emergency Management Bureau decided not to impose administrative penalties on the company, citing that the violation was minor and promptly corrected, with no harmful consequences [3] - WuXi AppTec provides integrated, end-to-end new drug research and production services globally, with operational bases in Asia, Europe, and North America, serving around 6,000 partners from over 30 countries [5] Group 2 - WuXi AppTec was established in 2000 with a registered capital of 2,933.34 million RMB, while Tianjin WuXi AppTec New Drug Development Co., Ltd. was founded in 2006 with a registered capital of 800 million RMB [6] - As of July 14, 2025, WuXi AppTec's stock price was 78.60 RMB, reflecting a 1.88% increase [7]

Group 1: Company Performance - Aopu Mai expects to achieve approximately 177 million yuan in revenue for the first half of 2025, representing a year-on-year growth of about 23.25% [1] - The company anticipates a net profit attributable to shareholders of approximately 37 million yuan, an increase of about 53.28% year-on-year [1] - Aopu Mai's net profit after deducting non-recurring gains and losses is expected to be around 29.03 million yuan, reflecting a year-on-year increase of approximately 73.46% [1] Group 2: Industry Trends - Multiple CXO companies have reported positive performance forecasts for the first half of 2025, indicating a potential turning point for the CXO industry [2] - WuXi AppTec expects to achieve approximately 20.64% year-on-year revenue growth, with adjusted net profit projected to increase by about 44.43% [2] - The overall market sentiment for the CXO sector is improving, driven by a recovery in global healthcare financing and a favorable domestic policy environment [3] Group 3: Market Dynamics - The global healthcare investment and financing amount is showing a recovery trend, with a projected growth rate of 25.3% in 2024 [3] - The domestic innovative drug sector is experiencing a positive market trend, with over 80 business development transactions in the first half of the year, significantly higher than the previous year's average [3] - Analysts suggest that the CXO sector may benefit from a chain of encouraging innovation policies and improved financing conditions, although there are concerns about market overheating [3]

無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2025年7月28日（星期一）召開董事會會議，以考 慮及批准（其中包括）本集團截至2025年6月30日止六個月之未經審計中期業績 及其發佈。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 董事會會議召開日期 * 僅供識別 李革博士 香港，2025年7月14日 於本公告日期，董事會包括本公司執行董事李革博士、陳民章博士、胡正國先生、楊青博士 及張朝暉先生；本公司非執行董事童小幪先生及吳亦兵博士；以及本公司獨立非執行董事 盧韶華女士、俞衛博士、張新博士、詹智玲女士及冷雪松先生。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月14日 第 1 頁 共 9 頁 v 1.3.0 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | | 購回股份(或其他證券)但沒有註銷 | | | | | | 2). | | 303,367 | 0.01 % ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月14日 第 3 頁 共 9 頁 v 1.3.0 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出 ...